12:00 AM
 | 
May 05, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); wingless-type MMTV integration site family member 3A (WNT3A); 7-dehydrocholesterol reductase (DHCR7); glycogen synthase kinase

Other

INDICATION: Genetic disorders

In vitro studies suggest activating Wnt/CTNNB1 signaling could help treat microcephaly associated with Smith-Lemli-Opitz syndrome, a developmental disorder caused by DHCR7 mutations. In patient-derived induced pluripotent stem (iPS) cells, levels of Wnt/CTNNB1 pathway...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >